Gene: MYOM2
Official Full Name: myomesin 2provided by HGNC
Gene Summary: The giant protein titin, together with its associated proteins, interconnects the major structure of sarcomeres, the M bands and Z discs. The C-terminal end of the titin string extends into the M line, where it binds tightly to M-band constituents of apparent molecular masses of 190 kD and 165 kD. The predicted MYOM2 protein contains 1,465 amino acids. Like MYOM1, MYOM2 has a unique N-terminal domain followed by 12 repeat domains with strong homology to either fibronectin type III or immunoglobulin C2 domains. Protein sequence comparisons suggested that the MYOM2 protein and bovine M protein are identical. [provided by RefSeq, Jul 2008]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO04628 | MYOM2 Knockout cell line (HCT 116) | Human | MYOM2 | 1:2~1:4 | Negative | Online Inquiry |
KO04629 | MYOM2 Knockout cell line (HEK293) | Human | MYOM2 | 1:3~1:6 | Negative | Online Inquiry |
KO04630 | MYOM2 Knockout cell line (A549) | Human | MYOM2 | 1:3~1:4 | Negative | Online Inquiry |
MYOM2 Gene Knockout Cell Lines represent a cutting-edge tool for gene functional studies, offering researchers a powerful means to investigate the role of the MYOM2 gene in muscle development and disease. These cell lines are engineered to possess a complete deletion of the MYOM2 gene, allowing for precise assessment of the gene's influence on myofibril assembly, muscle fiber maturation, and associated signaling pathways.
The key function of the MYOM2 gene knockout is to facilitate the investigation of gene function through gene expression analysis, protein characterization, and phenotypic assays. By studying these knockout cell lines, scientists can elucidate the mechanisms by which MYOM2 contributes to muscle integrity and pathology, providing insights into muscle-related disorders such as cardiomyopathies and muscular dystrophies. The ability to manipulate gene presence in a controlled environment allows for a clearer understanding of cellular responses and interactions, which is pivotal in expanding the current knowledge base of muscle biology.
In research settings, these cell lines can be utilized for high-throughput screenings, drug testing, and elucidating the disease mechanisms associated with MYOM2. Clinically, they pave the way for developing targeted therapies by enabling researchers to assess potential interventions on musculature affected by MYOM2-related dysfunction.
What sets MYOM2 Gene Knockout Cell Lines apart from other available options is the targeted approach combined with high fidelity in gene editing. These lines ensure a reliable and reproducible model that minimizes off-target effects often associated with less precise knockout methods. Furthermore, as part of our comprehensive product line, these cell lines are backed by extensive validation and characterized for performance, ensuring that researchers can trust their results.
Moreover, our company is committed to advancing biological research through high-quality products supported by decades of expertise in genetic engineering. With MYOM2 Gene Knockout Cell Lines, we provide a vital resource that empowers researchers and clinicians alike to push the boundaries of muscle biology research and therapeutic innovations.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.